Medicine details

ImageAmezol 400
NameAmezol 400
DosageTablet
Generic NameMetronidazole
Classes Antiinfective Agent
Dermatological/Topical Agent
Topical Antiinfective Agent
Antiprotozoal / Amebicide
Vaginal Preparation
Diseases Infectious Disease
RTI (Respiratory Tract Infection)
UTI (Urinary Tract Infection)
Vaginal Yeast Infection
CompanyCosmic Pharma Ltd.

Drug Package Details

Strength400 mg
Storage Condition
Origin CountryBangladesh
Commercial Pack100
Price per pack125.00
Cost per pack110.00
Package unit10 tabs strip
Price per unit1.25
Cost per unit1.10
Discount0
Coupon
Remarks

Metronidazole

 Metronidazole is an antibacterial agent belonging to the nitroimidazole class. Metronidazole inhibits protein synthesis by interacting with DNA and causing a loss of helical DNA structure and strand breakage.

  • Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy.
  • Metronidazole is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol and
    penicillin.
  • Intra-abdominal Infections, including peritonitis, intra-abdominal abscess and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus). Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species.
  • Skin and Skin Structure Infections caused by Bacteroides species including B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species and Fusobacterium species.
  • Gynecologic Infections, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species and Fusobacterium species.
  • Bacterial Septicemia
  • Bone and Joint Infections
  • Meningitis and brain abscess, caused byBacteroides species including the B. fragilis group.
  • Lower Respiratory Tract Infections, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group.
  • Endocarditis caused by Bacteroides species including the B. fragilis group.

Anaerobic infection prophylaxis is commonly used in the context of abdominal (particularly colorectal) and gynecological surgery.

  • Adults: 400 mg 8 hourly for 24 hours prior to surgery, then post-operative intravenous or rectal injection until the patient is able to consume tablets.
  • Pediatric population
    Children under the age of 12 years: a single dosage of 20–30 mg/kg given 1–2 hours before surgery.
    10 mg/kg body weight as a single dosage before operation for newborns with a gestational age of less than 40 weeks.

Anaerobic infections: A Flagyl treatment period lasts about 7 days, depending on the severity of the patient's disease as determined clinically and bacteriologically.

  • Adults: 800 mg followed by 400 mg every 8 hours for an established anaerobic infection.
  • Paediatric population

    Children > 8 weeks to 12 years of age: The usual daily dose is 20 – 30 mg/kg/day as a single dose or divided into 7.5 mg/kg every 8 hours. The daily dose may be increased to 40 mg/kg, depending on the severity of the infection. Duration of treatment is usually 7 days.

    Children < 8 weeks of age: 15 mg/kg as a single dose daily or divided into 7.5 mg/kg every 12 hours.

Commonly associated side effects include-

  • Metallic taste
  • nausea
  • vomiting
  • diarrhoea
  • drowsiness
  • rashes 
  • Patients having a history of hypersensitivity to metronidazole or other nitroimidazole derivatives should not use Metronidazole Injection, USP.
  • Patients who have taken disulfiram during the last two weeks should not be given metronidazole.
  • Peripheral neuropathy and encephalopathy: Metronidazole has been linked to encephalopathy and peripheral neuropathy (including optic neuropathy).
  • Metronidazole-treated patients have been known to experience convulsive seizures.
  • Metronidazole has been linked to cases of aseptic meningitis.
  • With products containing metronidazole for systemic use, incidents of severe hepatotoxicity/acute liver failure have been recorded, including cases with a fatal outcome with very rapid start after therapy commencement in individuals with Cockayne syndrome.
  • Metronidazole is metabolized slowly in patients with hepatic impairment, resulting in a buildup of metronidazole in the blood.

Contraindication

Contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives, such as-

 

Mteronidazole is contraindicated in alcoholic patients.

Metronidazole is containdicated in patients with severely compromised liver function.